Vivos Company Description
Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States.
The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals.
It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents; Duncan Chiller, a general laboratory equipment for non-water localized chilling; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Peltier Chiller brands.
The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017.
Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.
| Country | United States |
| Founded | 1994 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Michael Korenko |
Contact Details
Address: 1030 N Center Parkway Kennewick, Washington 99352 United States | |
| Phone | 509 222 2222 |
| Website | radiogel.com |
Stock Details
| Ticker Symbol | RDGL |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US92858K2042 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael K. Korenko Ph.D. | Chief Executive Officer and Director |
| Brad Allan Weeks | President |
| Dr. David J. Swanberg M.S., P.E. | Chief Operating Officer |
| Dr. Carlton M. Cadwell D.D.S. | Independent Chairman and Secretary |
| Michael H. Pollack CPA | Chief Financial Officer |
| Dr. Jim Duncan | Chief Technology Manager |